Health
NEW CEO, Martin Fitchet MD, brings over 25 years of experience across Pharmaceuticals, MedTech and Public Health Martin was most recently at Johnson & Johnson, where he was the Global Head of Global Public Health and also held multiple leadership roles in R&D His proven track record at Johnson & Johnson aligns perfectly with MMV’s mission and future strategy
MEDICINES for Malaria Venture, MMV, a leading not-for-profit partnership dedicated to combating malaria, has today announced the appointment of Martin Fitchet MD as its new Chief Executive Officer. CEO.
Martin brings over 25 years of experience across Pharmaceuticals, MedTech and Global Public Health and joins from Johnson & Johnson where he was most recently the Global Head of Global Public Health. Prior to that, Martin held multiple significant leadership roles at Johnson & Johnson, spearheading the development of and global access to novel pharmaceuticals for cardiovascular and metabolic diseases, HIV, tuberculosis, Ebola and Covid-19.
The new CEO joins as MMV celebrates its 25th anniversary and succeeds David Reddy, who was at the helm of the organisation for 13 years. During this period, MMV brought forward 15 new medicines estimated to have saved the lives of 15.4 million people.
Yet malaria remains an urgent and pressing global health issue that takes more than 600,000 lives a year. We must overcome the challenges posed by drug resistance, climate change and fragile health systems that limit access to medicines by the most vulnerable, notably children and pregnant women.
In his new role, Martin will oversee the development and delivery of new antimalarial medicines to help achieve a malaria-free future. This vision of the future is the linchpin of MMV’s new 2024-2030 strategy that will be launched at the Multilateral Initiative on Malaria Society Conference taking place in Rwanda from 21–27 April. The strategy lays out four pillars and cross-cutting priorities that will determine the organisation’s activity in the years ahead.
Martin Fitchet MD, CEO of MMV, said: “I am honoured and excited to join MMV, at such a pivotal time. In particular, I am inspired by the organisation’s relentless focus on harnessing innovation to save the lives of vulnerable and under-served populations at risk of malaria. I am committed to continuing this vital work and eager to begin working with the dedicated MMV team and partners, to accelerate efforts to help those most affected and to ultimately eradicate this disease.”
Alan Court, MMV Board Chair, said: “MMV’s Board is delighted that Martin has accepted the role of leading MMV. He succeeds David Reddy, to whom I offer my heartfelt thanks for his excellent leadership over the last 13 years. Martin’s expertise and proven track record of fostering innovation and access to medicines align perfectly with MMV’s strategic initiatives. I am confident that Martin, as a doctor and global health leader, will lead the organisation to deliver cutting-edge innovation to the populations that need it most.”
A.
-April 18, 2024 @ 13:46 GMT|
Tags: Alan Court Martin Fitchet
